HIND

Vyome Holdings, Inc. Common Stock
HIND

Overview Fund Activity
6.32 USD
+0.27
4.46%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
6.12
-0.20
3.16%
1 day
4.46%
5 days
-18.13%
1 month
-27.61%
3 months
-40.82%
6 months
-89.97%
Year to date
-98.61%
1 year
-99.32%
5 years
-100%
10 years
-100%
 

About: Vyome Holdings Inc is a clinical stage specialty pharmaceutical company working to treat immuno-inflammatory diseases including rare indications of unmet need with next-generation therapeutic solutions.

Healthcare Biotechnology
0
Funds holding %
of 7,463 funds
–
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

24% more capital invested

Capital invested by funds: $37.4K [Q1] → $46.5K (+$9.15K) [Q2]

0.33% more ownership

Funds ownership: 0.03% [Q1] → 0.36% (+0.33%) [Q2]

33% less funds holding

Funds holding: 6 [Q1] → 4 (-2) [Q2]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

See Fund Rankings

Financial journalist opinion

Based on 4 articles about HIND published over the past 30 days

Neutral
Business Wire
15 hours ago
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1). Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States.
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
Neutral
Business Wire
8 days ago
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a.
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
Neutral
Business Wire
13 days ago
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced the interim results from its investigator-initiated Phase 2 PoC study of VT-1953 topical gel in patients with malignant fungating wounds (“MFW”). The interim results were first presented at the recent annual meeting of the American Association for Cancer Research. Vyome Co-founder Dr. Shiladitya Sengupta will host a live video conference on Monday, September 8, to.
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
Neutral
Business Wire
27 days ago
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market. This partnership will combine Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to potentially productize and commercialize smart medical devices that can transfo.
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
Neutral
Business Wire
1 month ago
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced its Board of Directors has agreed to conduct a full review of strategic alternatives for Livechain Inc. (OTCID: LICH), a company in which Vyome is the controlling shareholder. “As promised, we are committed to our shareholders and maximizing shareholder value. Most of our shareholders are probably completely unaware that we are a 70% controlling sharehol.
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
Neutral
Business Wire
1 month ago
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, will be ringing the Nasdaq Opening Bell today in honor of its first day of trading as “HIND.” The occasion will also mark India's 79th Independence Day. “The HIND journey begins today, a journey in which anyone, anywhere in the world can now participate thanks to our stock being on.
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
See News Rankings
Charts implemented using Lightweight Charts™